Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010

SAN DIEGO, May 24, 2010 - Volcano Corporation (Nasdaq: VOLC) announced today the company's plans to
highlight its new product launches, presence in live cases, and participation
in late breaking trials during EuroPCR from May 25 - 28 in Paris.

"Through both imaging and therapy, Volcano continues to lead the way in
providing innovative solutions to best meet the complex needs of the
interventional vascular physician and their patients," said Michel Lussier,
Group President for Advanced Imaging Systems, Scientific Affairs, and Volcano
Europe, Africa, and the Middle East (EAME). "We look forward to furthering
the most progressive year of internally-developed technological innovations
our company has seen yet that address the limitations of angiography. Not
only do we continue to launch new-to-the-world technologies, we are also
pleased to further optimize already commercialized intravascular ultrasound
(IVUS) and fractional flow reserve (FFR) products to make some of our best
products even better."

Product Innovations

During EuroPCR, Volcano will showcase its new CE Mark approved additions
to its suite of integrated cath lab systems, coronary and peripheral IVUS
catheters, and physiology guide wires measuring both pressure and flow. The
new product introductions from Volcano are:

    - Eagle Eye(R) Platinum, an optimization of the #1 digital IVUS catheter,
      designed for improved deliverability with the convenience of radiopaque
      markers;
    - PrimeWire PRESTIGE(TM), the next generation FFR wire with enhanced
      torque response, vessel navigation and support for treating
      multi-vessel disease patients; and
    - The s5(TM)/s5i(TM) 3.2 software, which streamlines the workflow for
      both IVUS and FFR procedures and is compatible with more than 3,000
      Volcano systems installed worldwide.

Volcano will also highlight its extensive pipeline of imaging and therapy
products including the VIBE(TM) RX Vascular Imaging Balloon Catheter (which
is awaiting CE Mark approval), Optical Coherence Tomography (OCT), and
Forward Looking Imaging. All products will be available for demonstration at
Booth #M07, Level 2. Volcano's IVUS and FFR technologies will also be
highlighted in its partners' booths, including those of GE, Philips, and
Siemens.

Volcano and Siemens will demonstrate continued development efforts to
bring imaging co-registration to interventional cardiology. This technology
will allow physicians to see their angiographic roadmap images linked
side-by-side with the corresponding IVUS images in the cath lab. "Now, a
patient's medical record will be even more complete," said Dave Sheehan,
President of Volcano's IVUS and Physiology Businesses and Volcano Japan.
"Plus, physicians will now have an additional layer of real-time precision to
aid their strategic decision-making about how to best treat their patients."
Volcano and Siemens plan to demonstrate the co-registration application from
a live case in Erasmus University Medical Center in Rotterdam, the
Netherlands.

Live Case Transmissions

Throughout EuroPCR, Volcano technology, including FFR, IVUS, and Image
Co-Registration, will be featured in live case transmissions from around the
world.

Clinical Trial Updates

Volcano's proprietary VH(R) IVUS technology will be highlighted in two
Late Breaking Data presentations (Times are Central European Time; events are
at the Palais Des Congres De Paris):

VICTORY (VH In Carotids Observational Registry) is a European,
multi-center prospective registry for carotid plaque characterization by
VH(R) IVUS during carotid stenting. Data on VICTORY will be presented at
approximately 1:30 PM CET on Tuesday, May 25th, in Theatre Havane.

HEAVEN (Virtual histology evaluation of atherosclerosis regression during
atorvastatin and ezetimibe administration) is a Czech, prospective,
randomized, multicenter controlled study that uses VH(R) IVUS to measure the
changes of plaque volume and the changes of plaque composition during
atorvastatin and ezetimibe administration to the patient with stable angina.
Data on HEAVEN will be presented at 8:48 AM CET on Thursday, May 27th, in
Room Vendome.

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to
facilitate endovascular procedures, enhance the diagnosis of vascular and
structural heart disease and guide optimal therapies. The company's
intravascular ultrasound (IVUS) product line includes ultrasound consoles
that can be integrated directly into virtually any modern cath lab. Volcano
IVUS offers unique features, including both single-use digital and rotational
IVUS imaging catheters, and advanced functionality options, such as VH(R)
IVUS tissue characterization and ChromaFlo(R). Volcano also provides
Physiology consoles and single-use pressure and flow guide wires and is
developing a line of ultra-high resolution Optical Coherence Tomography (OCT)
systems and catheters. Currently, more than 5,200 Volcano IVUS and Physiology
systems are installed worldwide, with approximately half of Volcano's
revenues coming from outside the United States. Volcano's wholly-owned
subsidiary, Axsun Technologies, develops and manufactures optical monitors,
lasers and optical engines used in telecommunications, medical imaging,
spectroscopy and other industrial applications. For more information, visit
the company's website at www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Any statements
in this release regarding Volcano's business that are not historical facts
may be considered "forward-looking statements," including statements
regarding the potential benefits of the products and procedures described
above, further development and expansion, commercial release and market
adoption of the company's technology, and the impact of clinical and other
technical data. Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and uncertainties which may
cause Volcano's results to differ materially and adversely from the
statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from the results predicted are
detailed in the company's annual report on Form 10-K, quarterly report on
Form 10-Q and other filings made with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements which speak
only as of the date they are made. Volcano undertakes no obligation to update
any forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence of
unanticipated events.

Edrienne Brandon of Volcano Corporation, +1-858-720-4136